

Corp. Office : 2nd Floor, 'Dorr Oliver' House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai - 400 099.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : gufic@guficbio.com
CIN L65990MH1984PLCO33519

02/LEGAL/BSE/2015-16/GBSL

14th August, 2015

To,
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001

Scrip code: 509079

Dear Sir/Madam,

Sub: Outcome of the Board of Director's Meeting

With respect to the captioned matter, this is to inform you that meeting of the Board of Directors of the Company was held today, 14th August, 2015, at 4.30 p.m. at the Corporate Office of the Company.

Wherein the Board of Directors, among other items, approved the unaudited Financial Results for the quarter ended on 30th June, 2015. The copy of the said Results is enclosed herewith.

Kindly take the above on record.

Thanking You,
Yours truly,
For Gufic Biosciences Limited


Santosh Sharma
Company Secretary

Encl.: As Above

GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2015

Particulars	Quarter Ended 30.06.2015 Unaudited	Quarter Ended 31.03.2015 Audited	Quarter Ended 30.06.2014 Unaudited	For the Year Ended 31.03.2015 Audited
INCOME:				
Net Sales / Income from Operations (Net of Excise Duty)	3759.20	3547.55	3908.05	15142.61
Other Operating Income	8.40	6.90	2.06	32.53
Total Income from Operations (Net)	3767.60	3554.46	3910.11	15175.14
EXPENSES:				
Cost of Materials Consumed	1755.99	1133.87	1646.95	6579.76
Purchase of Stock-in-Trade	557.29	472.44	553.44	1670.77
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(680.64)	149.49	(1.65)	(130.68)
Employee Benefits Expenses	745.81	647.57	367.53	1933.33
Depreciation and Amortisation Expenses	92.36	77.29	99.24	385.21
Other Expenses	1023.04	867.28	949.89	3675.26
Total Expenses	3493.85	3347.94	3615.40	14113.66
Profit from Operations before Other Income, finance costs and Exceptional Items	273.75	206.52	294.70	1061.48
Other Income	1.98	21.28	29.24	37.18
Profit from ordinary activities before finance costs and exceptional items	275.73	227.80	323.95	1098.66
Finance Costs	114.73	127.87	105.85	446.08
Profit from ordinary activities after finance costs but before exceptional items	161.00	99.93	218.10	652.59
Exceptional Items	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	161.00	99.93	218.10	652.59
Current Tax	75.00	18.50	75.00	278.61
Deferred Tax	(18.03)	(32.14)	23.73	(48.84)
Short/(Excess) Tax Provisions of Earlier Years	0.00	3.34	0.00	7.08
Net Profit from Ordinary Activities After Tax	104.03	110.23	119.37	415.74
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00
Net Profit for the Period	104.03	110.23	119.37	415.74
Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	2040.52	1936.49	1966.72	1936.49
E.P.S	0.13	0.14	0.15	0.54
Public Shareholding				
-- Number of Shares of Rs 1 /- Each	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding				
a) Pledged / Encumbered				
-- Number of Shares of Rs 1 /- Each	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered				
-- Number of Shares of Rs 1 /- Each	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%

GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 30.06.2015

Particulars	Quarter Ended 30.06.2015 Unaudited	Quarter Ended 31.03.2015 Audited	Quarter Ended 30.06.2014 Unaudited	For the Year Ended 31.03.2015 Audited
SEGMENT REVENUE				
Sales & Service				
Pharma	3650.22	3213.91	3554.96	13922.95
Consumer	108.98	333.65	353.09	1219.66
Total	3759.20	3547.56	3908.05	15142.61
Unallocabel Income	10.38	28.18	31.30	69.71
Total Segment Revenue	3769.58	3575.74	3939.35	15212.32
SEGMENT RESULTS				
Pharma	720.92	612.79	693.20	2701.05
Consumer	12.04	43.41	37.30	136.97
TOTAL	732.96	656.20	730.50	2838.02
Less: Unallocated over heads	364.87	351.11	307.32	1354.15
Finance Charges	114.73	127.87	105.85	446.08
Depreciation	92.36	77.29	99.24	385.21
Tax provision	56.97	(10.30)	98.73	236.85
Net Profit after Tax	104.03	110.23	119.37	415.74

Notes forming part of the un-audited financial results for the quarter ended June 30, 2015

- The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on August 14, 2015.
- For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2015.
- The figures of the last quarter of financial year 2014-15 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2015 and the unaudited published year – to – date figures upto December 31, 2014 which were subject to limited review.
- Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on June 30, 2015: Nil.
- Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board
Gufic Biosciences Limited


Pankaj Gandhi
Whole-Time Director

Mumbai dated August 14, 2015